Lucence
PrivateLast Round
Series A
Extension
Nov 10, 2023
Total Funding Raised
$74.35M
Company Overview
Lucence is a precision oncology company that develops non-invasive liquid biopsy tests for early cancer detection and treatment selection.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lucence Comparables
Compare Lucence with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Predicine | 83% | |
| Circulogene | 83% | |
| Guardant Health | 80% |
Lucence Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 10, 2023 | ||||
| Series A | Nov 20, 2019 |
Key People
Founding team and executive leadership
Lucence Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chen Capital Ventures | Series A Extension |
| Heliconia Capital | Series A, Series A Extension |
| SGInnovate | Series A |
| Openspace Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2025
Grew 18% QoQ, from 83 to 98 employees.
- Jul 1, 2025
Monthly visitors increased 88% MoM, reaching 3,000.
Recent news
Latest coverage and updates
- launchesSep 22, 2026
Lucence Health Inc. will launch urine-based test for kidney, bladder and prostate cancer on Dec 31st '26.
Lucence Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Lucence's valuation, stock price, and market status.
Is Lucence a public or private company?
Lucence is a private company.
What is the current stock price of Lucence?
Lucence is a private company, so its shares have no public market price. Caplight tracks Lucence's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lucence worth (valuation)?
Valuation information for Lucence is not publicly available.
Can I buy Lucence stock?
Lucence shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lucence's last funding round?
Lucence's most recent funding round was Series A Extension on November 10, 2023.
Who are the main investors in Lucence?
Key investors in Lucence include Chen Capital Ventures, Heliconia Capital, Openspace Capital.
Will Lucence IPO soon?
No public IPO plans have been announced for Lucence.
How can I track Lucence secondary market activity?
Caplight tracks bids, offers, and trades in Lucence's shares on secondary markets.